2-((R)-2-amino-3-((S)-5-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenylamino)-1-methoxy-1,5-dioxopentan-2-ylamino)-3-oxopropylthio)ethyl tetradecanoate | 1610431-54-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-((R)-2-amino-3-((S)-5-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenylamino)-1-methoxy-1,5-dioxopentan-2-ylamino)-3-oxopropylthio)ethyl tetradecanoate
• 英文别名: 2-[(2R)-2-amino-3-[[(2S)-5-[4-[[6-amino-2-(butylamino)-8-oxo-7H-purin-9-yl]methyl]anilino]-1-methoxy-1,5-dioxopentan-2-yl]amino]-3-oxopropyl]sulfanylethyl tetradecanoate
• CAS: 1610431-54-3
• 化学式: C₄₁H₆₅N₉O₇S
• 分子量: 828.089
• InChiKey: KKKMWQQUTYVFJT-ACHIHNKUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  58
• 可旋转键数：
  32
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  258
• 氢给体数：
  6
• 氢受体数：
  13

文献信息

• CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS
  申请人：CAYLA

  公开号：US20140141033A1

  公开（公告）日：2014-05-22

  A conjugated compound of formula Q-Z—R 4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R 4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

  一种配方为Q-Z—R4的共轭化合物，其中Q是TLR7和/或TLR8激动剂，Z—R4是TLR2激动剂，以及它们在治疗感染、癌症或免疫紊乱或用于疫苗中的用途。
• Conjugated TLR7 and/or TLR8 and TLR2 agonists
  申请人：Invivogen

  公开号：EP2732825A1

  公开（公告）日：2014-05-21

  The present invention relates to a conjugated compound of formula Q-Z-R4 wherein Q is a TLR7 and/or TLR8 agonist and Z-R4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

  本发明涉及一种式 Q-Z-R4 的共轭化合物（其中 Q 为 TLR7 和/或 TLR8 激动剂，Z-R4 为 TLR2 激动剂）及其在治疗感染、癌症或免疫紊乱或疫苗中的用途。
• Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
  申请人：Invivogen

  公开号：EP2732825B1

  公开（公告）日：2015-07-01
• SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
  申请人：Children's Hospital of Eastern Ontario Research Institute Inc.

  公开号：US20170239347A1

  公开（公告）日：2017-08-24

  The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.
• US9567336B2
  申请人：——

  公开号：US9567336B2

  公开（公告）日：2017-02-14